CompletedNot Applicable

Artificial Intelligence for the Prioritization of Genetic Background in Brugada Syndrome

Italy200 participantsStarted 2018-12-19

Plain-language summary

Brugada Syndrome (BS) is an inherited heart condition that can cause sudden cardiac arrest in young individuals. It's diagnosed through specific changes seen on an electrocardiogram (ECG). Currently, the only treatment option is a cardioverter defibrillator (ICD). Despite advances, much about BS remains unclear, including its genetic basis. This study aims to use advanced genetic sequencing and artificial intelligence to uncover new genetic factors contributing to BS. By understanding these factors better, we hope to improve risk assessment and treatment for affected individuals.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * The 200 BS patients have been selected and clinically evaluated based on the presence of a type I electrocardiogram (ECG), either spontaneous or induced by flecainide or ajmaline. Exclusion Criteria: * No exclusion criteria are adopted for this study. The entire previously sequenced cohort of 200 BS patients will be investigated and considered, exploiting AI approach for the prioritization of the sequencing available data.

What they're measuring

New candidate genes, likely associated with Brugada Syndrome using an AI based approach.

Timeframe: 1 year

Trial details

NCT IDNCT06376552

SponsorIRCCS San Raffaele

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-06-06

View on ClinicalTrials.gov More Brugada Syndrome trials